- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Spinocerebellar Ataxia Type 1.
Displaying page 1 of 1.
EudraCT Number: 2017-001481-23 | Sponsor Protocol Number: P160927J | Start Date*: 2017-09-12 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED CLINICAL TRIAL WITH RILUZOLE IN SPINOCEREBELLAR ATAXIA TYPE 2 | |||||||||||||
Medical condition: SCA2 patients, both gender, at least 18 years of age | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002618-38 | Sponsor Protocol Number: 721 | Start Date*: 2020-06-25 | |||||||||||
Sponsor Name:ASSOCIAZIONE "LA NOSTRA FAMIGLIA" - SEZIONE SCIENTIFICA I.R.C.C.S. "E.MEDEA" | |||||||||||||
Full Title: Clinical trial - phase II - to test safety and efficay of Etravirine's treatment in Friedreich Ataxia's patients | |||||||||||||
Medical condition: Friedreich's ataxia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016317-20 | Sponsor Protocol Number: SCA_LITIO_12 | Start Date*: 2009-10-26 | |||||||||||
Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II | |||||||||||||
Full Title: PILOT STUDY TO ASSESS SAFETY AND TOLERABILITY OF LITHIUM ON SPINOCEREBELLAR ATAXIA OF TYPE 2 | |||||||||||||
Medical condition: Spinocerebellar ataxia type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001314-19 | Sponsor Protocol Number: VO659-CT01 | Start Date*: 2023-04-25 | ||||||||||||||||
Sponsor Name:VICO Therapeutics B.V. | ||||||||||||||||||
Full Title: A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with sp... | ||||||||||||||||||
Medical condition: spinocerebellar ataxia types 1, 3 and Huntington’s disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) IT (Prematurely Ended) DK (Trial now transitioned) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000460-34 | Sponsor Protocol Number: ALCAT | Start Date*: 2015-11-18 |
Sponsor Name:Hospital of the University of Munich | ||
Full Title: Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) | ||
Medical condition: Cerebellar ataxia is a form of ataxia originating in the cerebellum and is most often caused by neurodegenerative disorders of the cerebellum, either hereditary or sporadic. The leading clinical sy... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000282-37 | Sponsor Protocol Number: AIFA-2016-02365063 | Start Date*: 2020-02-26 | |||||||||||
Sponsor Name:DIPARTIMENTO DI NEUROSCIENZE SALUTE MENTALE E ORGANI DI SENSO - NESMOS - SAPIENZA UNIVERSITÀ DI ROMA | |||||||||||||
Full Title: Riluzole (Glentek) in patients with SpinoCerebellar Ataxia type 7: a randomized, double-blind, placebo-controlled pilot trial with a lead in phase | |||||||||||||
Medical condition: Spinocerebellar ataxia type 7 (SCA7) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005356-10 | Sponsor Protocol Number: IB1001-301 | Start Date*: 2022-03-15 | |||||||||||
Sponsor Name:IntraBio Ltd | |||||||||||||
Full Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover study | |||||||||||||
Medical condition: Niemann-Pick Disease type C (NPC) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004331-71 | Sponsor Protocol Number: IB1001-201 | Start Date*: 2019-05-08 | |||||||||||
Sponsor Name:IntraBio Ltd | |||||||||||||
Full Title: Effects of N-Acetyl-L-Leucine on Niemann-Pick type C Disease (NPC): A multinational, multi-center, open-label, rater-blinded Phase II study | |||||||||||||
Medical condition: Niemann-Pick Disease type C (NPC) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004406-25 | Sponsor Protocol Number: IB1001-202 | Start Date*: 2019-05-09 | |||||||||||
Sponsor Name:IntraBio Ltd | |||||||||||||
Full Title: Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A multinational, multicenter, open-label, rater-blinded Phase II study. | |||||||||||||
Medical condition: GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003136-25 | Sponsor Protocol Number: CTD-TCNPC-301 | Start Date*: 2021-10-25 | |||||||||||
Sponsor Name:Cyclo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Double blind, Randomized, Placebo controlled, Parallel group, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of 2000 mg/kg of Trappsol® Cyclo™ (Hydroxypropyl β cycl... | |||||||||||||
Medical condition: Niemann Pick Disease Type C1 | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
